Journal Article

Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial

Valentin, Thibaud, Filleron, Thomas, Lodin, Sabrina, Mounier, Muriel, Poublanc, Muriel, Chevreau, Christine, Le Guellec, Sophie, Massoubre, Angélique, Chibon, Frédéric, Lesluyes, Tom, Cabarrou, Bastien

2020

Overview

Background The value of chemotherapy in soft tissue sarcoma (STS) remains controversial. Several expert teams consider that chemotherapy provides a survival advantage and should be proposed in high-risk (HR) patients. However, the lack of accuracy in identifying HR patients with conventional risk factors (large, deep, FNCLCC grade 3, extremity STS) is an issue that cannot be neglected. For example, while the FNCLCC grading system is a powerful tool, it has several limitations. CINSARC, a 67-gene signature, has proved to be an additional independent factor for predicting metastatic spread and outperforms histological grade. Regardless of FNCLCC grade, CINSARC stratifies patients into two separate prognostic groups: one with an excellent prognosis (low-risk (LR) CINSARC) and the other with a worse outcome (HR-CINSARC) in terms of metastatic relapse. Here we evaluate the role of chemotherapy in grade 1–2 STS patients with HR-CINSARC and assess the prognostic value of CINSARC in patients treated with standard of care. Methods CHIC is a parallel, randomized, open-label, multicenter study evaluating the effect on metastasis-free survival of adding perioperative chemotherapy to standard of care in patients with grade ½ STS sarcoma defined as HR by CINSARC. In this target selection design, 600 patients will be screened with CINSARC to randomize 250 HR-CINSARC patients between standard of care and standard of care plus chemotherapy (4 cycles of 3 weeks of intravenous chemotherapy with doxorubicin in combination with dacarbazine or ifosfamide according to histologic subtype). LR-CINSARC patients will be treated by standard of care according to the investigator. The primary endpoint is metastasis-free survival. Secondary endpoints include overall survival, disease-free survival and safety. Furthermore, the prognostic value of CINSARC will be evaluated by comparing LR-CINSARC patients to HR-CINSARC patients randomized in standard of care. Discussion CHIC is a prospective randomized phase III trial designed to comprehensively evaluate the benefit of chemotherapy in HR-CINSARC patients and to prospectively validate the prognostic value of CINSARC in grade ½ STS sarcoma patients. Trial registration ClinicalTrials.gov identifier: NCT04307277 Date of registration: 13 March 2020

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Anthracyclines / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biomarkers / Biomedical and Life Sciences / Biomedicine / Biopsy / Cancer metastasis / Cancer Research / Care and treatment / Chemotherapy / CINSARC signature / Clinical trials / Clinical Trials, Phase III as Topic / Dacarbazine / Dacarbazine - therapeutic use / Disease-Free Survival / Doxorubicin / Doxorubicin - therapeutic use / Gene expression / Health Promotion and Disease Prevention / Humans / Hypotheses / Ifosfamide / Ifosfamide - therapeutic use / Intravenous administration / Life Sciences / Medical prognosis / Medical research / Medicine/Public Health / Metastases / Metastasis / Multicenter Studies as Topic / Nanotechnology - methods / Neoplasm Grading - methods / Objectives / Oncology / Paraffin Embedding / Perioperative Care - methods / Prognosis / Radiation therapy / Randomized Controlled Trials as Topic / Reproducibility of Results / Risk Factors / Sarcoma / Sarcoma - drug therapy / Sarcoma - genetics / Sarcoma - mortality / Sarcoma - pathology / Soft Tissue Neoplasms - drug therapy / Soft Tissue Neoplasms - genetics / Soft Tissue Neoplasms - mortality / Soft Tissue Neoplasms - pathology / Soft tissue sarcoma / Studies / Study Protocol / Surgical Oncology / Survival / Target selection design / Transcriptome / Tumors